Ocular Physiologically Based Pharmacokinetic Modeling for Ointment Formulations.
PBPK
ocular PBPK
ophthalmic ointment
product development
Journal
Pharmaceutical research
ISSN: 1573-904X
Titre abrégé: Pharm Res
Pays: United States
ID NLM: 8406521
Informations de publication
Date de publication:
19 Nov 2020
19 Nov 2020
Historique:
received:
05
08
2020
accepted:
27
10
2020
entrez:
20
11
2020
pubmed:
21
11
2020
medline:
5
8
2021
Statut:
epublish
Résumé
The purpose of this study is to show how the Ocular Compartmental Absorption & Transit (OCAT™) model in GastroPlus A newly OCAT™ model developed for fluorometholone, as well as a previously verified model for dexamethasone, were used to characterize the aqueous humor (AH) concentration following the administration of multiple ointment formulations to rabbit. The model uses the following parameters: application surface area (SA), a fitted application time, and the fitted Higuchi release constant to characterize the rate of passage of the active pharmaceutical ingredient from the ointment formulations into the tears in vivo. Parameter sensitivity analysis was performed to understand the impact of ointment formulation changes on ocular exposure. While application time was found to have a significant impact on the time of maximal concentration in AH, both the application SA and the Higuchi release constant significantly influenced both the maximum concentration and the ocular exposure. This initial model for ointment ophthalmic formulations is a first step to better understand the interplay between physiological factors and ophthalmic formulation physicochemical properties and their impact on in vivo ocular drug pharmacokinetic performance in rabbits.
Identifiants
pubmed: 33215336
doi: 10.1007/s11095-020-02965-y
pii: 10.1007/s11095-020-02965-y
pmc: PMC7677276
doi:
Substances chimiques
Glucocorticoids
0
Ointments
0
Dexamethasone
7S5I7G3JQL
Fluorometholone
SV0CSG527L
Types de publication
Comparative Study
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
245Subventions
Organisme : U.S. Food and Drug Administration
ID : HHSF223201810255P
Références
Acta Ophthalmol (Copenh). 1989 Feb;67(1):51-4
pubmed: 2505485
AAPS J. 2019 May 20;21(4):65
pubmed: 31111305
J Pharm Sci. 1998 Dec;87(12):1479-88
pubmed: 10189253
Adv Drug Deliv Rev. 2018 Feb 15;126:23-43
pubmed: 29247767
J Pharm Sci. 1961 Oct;50:874-5
pubmed: 13907269
J Pharmacokinet Pharmacodyn. 2020 Dec;47(6):597-612
pubmed: 32876799
Adv Exp Med Biol. 1997;423:269-88
pubmed: 9269503
J Pharm Sci. 1984 Aug;73(8):1021-7
pubmed: 6491903
Arch Ophthalmol. 1993 Sep;111(9):1210-8
pubmed: 8363464
Int J Pharm. 2015 Oct 15;494(1):31-9
pubmed: 26241753
J Pharm Sci. 1978 May;67(5):603-6
pubmed: 641790
Eur J Pharm Biopharm. 2015 Sep;95(Pt B):215-26
pubmed: 25603198
Pharm Res. 2018 May 31;35(8):153
pubmed: 29855726
Int J Pharm. 2015 Nov 30;495(2):783-91
pubmed: 26343911
Pharm Res. 2016 Nov;33(11):2680-90
pubmed: 27431864
Drug Metab Dispos. 2015 Nov;43(11):1823-37
pubmed: 26296709
Invest Ophthalmol Vis Sci. 1993 Jun;34(7):2251-9
pubmed: 8505206
Int J Pharm. 2015 Sep 30;493(1-2):412-25
pubmed: 26231106
J Pharm Sci. 1986 Mar;75(3):280-7
pubmed: 3701612
J Pharm Sci. 1976 Dec;65(12):1816-22
pubmed: 1032669
AAPS J. 2020 Jan 6;22(2):26
pubmed: 31907674
Pharm Res. 1993 Apr;10(4):616-20
pubmed: 8483849
Drug Discov Today. 2019 Aug;24(8):1587-1597
pubmed: 30959112
Int J Pharm. 2011 Oct 10;418(1):6-12
pubmed: 21458553
J Pharm Sci. 2019 Jan;108(1):620-629
pubmed: 30385283
J Pharm Sci. 1981 Sep;70(9):1026-9
pubmed: 6101147
Surv Ophthalmol. 1978 Mar-Apr;22(5):335-40
pubmed: 653578
Pharm Res. 2018 Nov 15;36(1):13
pubmed: 30443681
Arch Ophthalmol. 1975 Jan;93(1):42-5
pubmed: 1111487
J Pharm Sci. 1975 Jun;64(6):931-6
pubmed: 1133744
Pharm Res. 1993 Sep;10(9):1308-14
pubmed: 8234168
Mol Pharm. 2017 Aug 7;14(8):2690-2696
pubmed: 28631484
AAPS J. 2016 Jul;18(4):1032-8
pubmed: 27184578